bullish

Revolution Medicines

2023 High Conviction: Revolution Medicines – Cracking The KRAS In Cancer

Oncology-focused unicorn Revolution Medicines is our high-risk/high-reward conviction idea for 2023 as we see room for further gains among select names in the oncology biotech industry in the U.S.

Equity Bottom-Up
360 Views, 25 Nov 2022 01:30
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Andrei Zakharov
Director of Equity Research, IPOs
Algosun Global
Information Technology & EnergyEquitiesEquity Capital MarketsThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • 2023 High Conviction: Revolution Medicines – Cracking The KRAS In Cancer
    25 Nov 2022
x